1
answer
0
watching
152
views
3 Mar 2019
Interpret/delineate Pharmacogenomics in the following:
29-yo Japanese individual is seeking treatment for breast cancer. Treatment regimen with Tegafur was recommended, and Uracil was included as an adjuvant. The individual was identified as a homozygous carrier of LoF variant of CYP2A6*4. Predict and discuss the therapeutic outcome of Tegafur treatment in this individual. (Provide a schematic of tamoxifen metabolism by CYP2D6. Characterize the phenotype of the individual with reference to the drug being received and identify the drug-gene interaction; Comment on pharmacokinetic profile. Predict the therapeutic outcome of this treatment if a standard dose of the drug is received based on the clinical presentation of the disease).
Interpret/delineate Pharmacogenomics in the following:
29-yo Japanese individual is seeking treatment for breast cancer. Treatment regimen with Tegafur was recommended, and Uracil was included as an adjuvant. The individual was identified as a homozygous carrier of LoF variant of CYP2A6*4. Predict and discuss the therapeutic outcome of Tegafur treatment in this individual. (Provide a schematic of tamoxifen metabolism by CYP2D6. Characterize the phenotype of the individual with reference to the drug being received and identify the drug-gene interaction; Comment on pharmacokinetic profile. Predict the therapeutic outcome of this treatment if a standard dose of the drug is received based on the clinical presentation of the disease).
Nestor RutherfordLv2
5 Mar 2019
